Phase II Clinical Trial Design for Noncytotoxic Anticancer Agents for Which Time to Disease Progression Is the Primary Endpoint-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II Clinical Trial Design for Noncytotoxic Anticancer Agents for Which Time to Disease Progression Is the Primary Endpoint

Published:2000-08 Issue:4 Volume:21 Page:343-359
ISSN:0197-2456
Container-title:Controlled Clinical Trials
language:en
Short-container-title:Controlled Clinical Trials

Author:

Mick Rosemarie,Crowley John J,Carroll Raymond J

Publisher

Elsevier BV

Subject

Pharmacology

Reference36 articles.

1. Statistical aspects in the design and analysis of phase II clinical trials;Herson,1984

2. Methods in Clinical Oncology;Leventhal,1988

3. How large should a phase II trial of a new drug be?;Simon;Cancer Treatment Rep,1987

4. Incorporating historical control data in planning phase II clinical trials;Thall;Stat Med,1990

5. Optimal two-stage designs for phase II clinical trials;Simon;Control Clin Trials,1989

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience;Cancers;2024-01-09

2. Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma;Clinical Cancer Research;2023-06-02

3. Estimating the distribution of ratio of paired event times in phase II oncology trials;Statistics in Medicine;2022-12-27

4. The progression-free survival ratio as outcome measure in recurrent ovarian carcinoma patients: Current and future perspectives;Gynecologic Oncology Reports;2022-08

5. In search of effective therapies: the current landscape of phase II trials in patients with advanced soft tissue sarcoma;Journal of Cancer Research and Clinical Oncology;2022-07-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3